TCT-338 Meta-analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Patients with Diabetes and Left Main and/or Multivessel Coronary Artery Disease  by Zhou, Yu Jie et al.
pathology. To refresh the imaging data, patient can be moved from ISS to MC suites, data
acquisition takes place, and the patient is then returned to the ISS where the new MR
imaging data can be used to complete the procedure.
Results: The current set up also permits utilisation of PET in conjunction with ISS
procedures, e.g., as the final imaging modality to control whether PET-enhancing
pathology was completely removed or angioplasty perfoemd. For instance, after comple-
tion of ablation under MR imaging, the patient can be moved into the PET/CT suite. A
PET image produced after tracer injection and uptake can then be used to assess the
completeness of the ablation procedure.
Conclusions: A room layout combining 3T MRI and PET/CT with other interventional
modalities (e.g., fluoroscopy, ultrasound, CT) has been realized for integrated multimo-
dality image-guided diagnosis and therapy of cardiovascular diseases. Such a design
enables corollary studies into novel workflows for taking full advantage of the integrated
design.
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Background: Patient-specific rehearsal (PsR) of an endovascular aortic aneurysm repair
(EVAR) enables the interventionalist to practice the case prior to treat the real patient.
This pilot study aimed to evaluate if PsR for EVAR is feasible, influences technical
performance, to evaluate face validity and the subjective sense of utility.
Methods: Patients with an AAA suitable for EVAR with the Gore C3 Excluder (W.L.
Gore & Assoc, Sunnyvale, California, USA) were enrolled in three centres. A 3D model
of the patient’s anatomy was generated using the PROcedure rehearsal software within the
Angiomentor (Simbionix, Ohio, Cleveland). Less than 24 hours before the real case,
rehearsals were conducted in the Laboratory or Angiosuite. Technical metrics were
recorded. All team members completed a questionnaire evaluating the EVAR experience.
A subjective questionnaire was used to evaluate the realism, technical and human factor
aspects.
Results: Nine patients were enrolled. EVAR procedures were performed by 7 different
teams. 6/8 lead interventionalists were highly experienced in EVAR ( 50 cases). In 7/8
patients, the rehearsal significantly changed the optimal position of the C-arm to
maximally cover the proximal and contralateral landing zones. In 6/8 and 5/8 patients
respectively, an identical oblique or cranio-caudal fluoroscopy angle was chosen in real
life. All team members found the rehearsal useful for selecting the optimal fluoroscopy
angle (median 4, IQR 4-5). The realism of the EVAR procedure simulation was rated
highly (median 4, IQR 3-4). All team members found the PsR useful to optimally prepare
the entire team (median 4, IQR 4-5). The choice of the tool kit (median 2, IQR 1.5-3) nor
the diameter of the device (median 2, IQR 2-3) was likely to be altered by the rehearsal.
Conclusions: PsR for EVAR is feasible and permits creation of realistic case studies.
Subjective evaluation indicates that it may influence optimal C-arm angles, be useful for
preoperative case review and valuable to prepare the entire team. However, a RCT is
required to evaluate how this technology may influence technical and team performance
ultimately leading to improved patient outcomes and increased safety.
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Background: Diabetes is associated with a higher risk of adverse events following
PCI with drug eluting stents (DES). Within the TWENTE trial, a randomized trial
comparing zotarolimus-eluting Resolute and everolimus-eluting Xience V stents,
a significant interaction was seen between diabetes and DES type with regard to
target vessel failure (TVF). In diabetics, safety and efficacy data of these DES are
scarce.
Methods: In this post-hoc analysis of TWENTE, clinical outcome of both DES in
diabetic (n301; 36.2% insulin-treated) and non-diabetic patients (n1090) was com-
pared. Clinical endpoints were adjudicated by an independent, external events committee.
Multivariate logistic regression analyses were performed to adjust for differences in
baseline variables.
Results: Groups stratified by DES were similar except for a higher prevalence of
hypercholesterolemia in non-diabetic patients of the Xience V arm (p0.04) and calcified
target lesions in diabetic patients of the Resolute arm (p0.04). In both diabetics and
non-diabetic patients, multivariate analysis indicated no significant difference in clinical
outcome between DES. Within non-insulin-treated diabetics, there was also no significant
between-stent difference in clinical outcome. However, in insulin-treated diabetics, the
Resolute arm showed higher rates of target vessel failure (TVF)(28.3% vs 7.3%,
p0.015), target-lesion failure(26.4% vs. 5.5%, p0.016), and patient oriented composite
endpoint(32.1% vs. 10.9%, p0.02). A significant interaction was observed between
insulin treatment and DES type for TVF (p0.029). In Resolute treated patients,
insulin-treated diabetics had a higher rate of TVF compared to non-diabetics and
non-insulin-treated diabetics (p0.001). In the Xience V arm, rates of TVF were similar
across all subgroups.
Conclusions: In non-diabetic patients and non-insulin-treated diabetics, Resolute and
Xience V showed no significant difference in safety and efficacy up to 12 months. In the
limited number of insulin-treated diabetics, Resolute was associated with inferior clinical
outcome. This hypothesis-generating finding requires confirmation in large randomized
trials.
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Artery Bypass Graft Surgery in Patients with Diabetes and Left Main and/or
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Yu Jie Zhou1, Fei Gao2, Zhijian Wang2
1An Zhen Hospital, Capital Medical University, Beijing, China, Beijing, China,
2Anzhen Hospital affiliated with Capital Medical University, Beijing, Beijing
Background: The optimal coronary revascularization strategy for patients with diabetes
and left main and/or multivessel disease is undetermined. The aim of our study was to
evaluate percutaneous coronary intervention (PCI) versus coronary artery bypass graft
(CABG) in those patients.
Methods: We identified 13 articles, published before Oct 2011, enrolling 6992 patients,
follow-up period ranged from 1 to 5 years.
Results: Patients with PCI had a significant reduction in cerebral vascular attack (CVA)
(OR 0.29, 95% CI 0.16 to 0.51, p0.0001, I2 0%) as compared with CABG, whereas
there was a four-fold increased risk of repeat revascularization associated with PCI even
using drug-eluting stent (OR 4.44, 95% CI 3.42 to 5.78, chi2 4.92, p0.00001, I2 0%).
The overall mortality (OR 0.97, 95% CI 0.81 to 1.15, p0.70, I2 0%) was
comparable between the PCI and CABG. However, in subgroup analysis, the
composite outcome (death/myocardial infarction/CVA) was significantly reduced in
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favor of DES implantation (OR 0.79, 95% CI 0.63 to 0.99, chi2 1.07, p0.04,
I2 0%).
Conclusions: Our study confirmed the cerebral vascular benefits of PCI by
significantly reducing CVA risks, and the composite outcome was better in
patients undergoing PCI with drug-eluting stent despite a higher repeat revascu-
larization rate. It poses imperative demands for future prospective randomized
studies to define the optimal strategy in patients with diabetes and left main and/or
multivessel disease.
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Background: The aim of this study is to compare the one year clinical outcomes in
patients with chronic total occlusion (CTO) lesion between diabetic and non-diabetic.
Methods: A total 3890 patients (Age; 62.99  11.04, Men; 74.1 %) with chronic total
occlusion were analyzed. The patients were divided into a diabetic group (n  2,579
patients) and a non-diabetic group (n 1,401 patients).We evaluated the one year clinical
outcomes including target lesion revascularization (TLR) and major adverse cardiac
events (MACEs) between the two groups.
Results: One year after PCI, 319 All-MACEs were developed. TLR and All-MACEs was
higher in diabetic group compared with that in non-diabetic group (respectively, 6.3 % vs.
8.9 %, p  0.022 and 12.2 % vs. 15.1%, p  0.047). In multivariate analysis, diabetic
mellitus was an independent predictor for one year TLR (OR; 1.414, p0.036) and
All-MACEs (OR; 1.743, p0.018).




OR ratio for 12-
month All-MACEs p
Age 0.999 (0.984-1.014) 0.887 0.993 (0.969-1.016) 0.948
Male 0.849 (0.591-1.220) 0.377 1.020 (0.564-1.843) 0.536
PCI Hx 0.916 (0.633-1.325) 0.641 0.859 (0.463-1.595) 0.631
HTN 1.012 (0.719-1.424) 0.946 0.839 (0.518-1.357) 0.474
CHF 1.836 (1.070-3.153) 0.028 1.050 (0.407-2.708) 0.920
DM 1.414 (1.023-1.953) 0.036 1.743 (1.102-2.758) 0.018
Conclusions: This study identified diabetic mellitus as an independent risk factor for one
year TLR and All-MACEs in patients with CTO lesion.
TCT-340
Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus
Durable Polymer Everolimus-Eluting Stents in Diabetic Patients - A
Prospective Non-Randomized Single Center Long Term Comparison
Pierre Sprimont1, Christophe de Meester1, Jean Renkin1, Olivier Gurne1,
Joelle Kefer1, Patrick Chenu1, Jean Louis Vanoverschelde1, Nadia Debbas1
1Cliniques Universitaires Saint Luc, Brussels, Belgium
Background: Biodegradable polymer drug eluting stents improve safety and efficacy when
compared to durable polymer drug eluting stents, but this may not be true in diabetic patients.
Methods: This prospective single center registry compared primary efficacy composite
end point of cardiac death, myocardial infarction and clinically indicated target-lesion
revascularization, primary safety end point defined as the rate of stent thrombosis and long
term survival in diabetic patients (pts) receiving biodegradable polymer Biolimus-Eluting
Stents (BES) or durable polymer Everolimus-Eluting Stents (EES).
Results: A total of 278 stents (133 BES and 145 EES) were implanted in 251 diabetic pts
(179 males, 6% type 1 diabetes) aged 6610 years who presented with Acute Coronary
Syndrome (n64, 25%) or stable angina (n133, 53%). Multiple vessel disease was present
in 63% pts. Vessels treated were 114 Left Anterior Descending, 76 Circumflex, 77 Right
Coronary, 8 Left Main. Dual antiplatelet therapy was given for at least 12 months. Baseline
clinical characteristics, cardiovascular risk factors, lesions location and classification were not
statistically significantly different in the two groups receiving BES (Group 1, n118 pts) and
EES (Group 2, n133 pts). At the end of the follow-up-period [median 19 (0-44) months], no
statistically significant difference was found in the occurrence of the primary efficacy
composite end point in the 2 groups (8.5% in Group 1 versus (vs) 12.3% in Group 2, p0.65),
nor in the occurrence of the primary safety end point (1.7% in Group 1 vs 1.8% in Group 2,
p0.22). There was no difference in cardiac death (2.5% in Group 1 vs 2.6% in Group 2,
p0.64), myocardial infarction (4.1% in Group 1 vs 3.6% in Group 2, p0.42), target vessel
revascularization (10% in Group 1 vs 11% in Group 2, p0.95) and target lesion revascular-
ization (7% in Group 1 vs 8% in Group 2, p0.82). The overall survival (Kaplan Meyer) was
not significantly different in both groups (log rank0.53).
Conclusions: In conclusion, clinical efficacy and safety of new generation biodegradable
polymer BES and durable polymer EES are similar in diabetic pts confirming that diabetes
is an entity in terms of coronary artery disease.
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